A novel prognostic biomarker for muscle invasive bladder urothelial carcinoma based on 11 DNA methylation signature. Issue 12 (1st December 2020)

• Record Type: Journal Article
• Authors: Feng, Yueyi; Jiang, Yiqing; Feng, Qingting; Xu, Lingkai; Jiang, Yun; Meng, Fang; Shu, Xiaochen
• Is Part Of: Cancer biology & therapy. Volume 21:Issue 12(2020)
• Page Start: 1119
• Page End: 1127
• Publication Date: 2020-12-01
• Subjects: Muscle invasive bladder urothelial carcinoma (MIBC) -- methylation -- nomogram -- prognostic -- risk model; 616.99406
• DOI: 10.1080/15384047.2020.1833811
• Languages: English
• ISSNs: 1538-4047

Abstract

ABSTRACT: Muscle-invasive bladder urothelial carcinoma (MIBC) is a highly invasive cancer, which leads to prevalent recurrence and poor prognosis. Exploring the association of DNA methylation and the prognosis of MIBC will thus be of important value in clinical management and treatment. Bumphunter method and adaptive lasso regression were used to explore the relationship between different methylation regions (DMRs) and the prognosis of MIBC. Next, we constructed a risk prognosis model and validated this model. Moreover, the performance of this risk model was examined by using time-dependent receiver operating characteristic curve (ROC). We identified 58, 449 different methylation sites and 490 different methylation regions. Among them, 11 DMRs were associated with the prognosis of MIBC through rigorous screening. Through the linear combination of 11 DMRs, a putative marker was developed, which can distinguish the survival risk in both the training dataset (HR = 2.58, 95% CI = (1.64, 4.05)) and the verification dataset (HR = 2.77, 95% CI = (1.25, 6.15)). Relatively high predictive values were observed from this model for training dataset (AUC = 0.791) and verification dataset (AUC = 0.668). Stratified analysis showed that the association was independent of gender. A nomogram was additionally generated to predict 5-year survival probability containing risk score and pathological stage. Its performance was evaluated by applying calibration curve. The methylation signature risk model based on 11 DMRs may be a reliable prognostic signature for MIBC, which provides new insights into development of individualized therapy for MIBC.